{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:47:08Z","timestamp":1793641628801,"version":"4.5.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In patients with acute lymphoblastic leukemia (ALL), treatment response is increasingly evaluated with minimal residual disease (MRD) assays. ALL cells can be recognized by their clonal rearrangement of immunoglobulin and T-cell receptor genes, expression of gene fusions, and leukemia-associated immunophenotypes. Assays based on polymerase chain reaction or flow cytometry can detect one ALL cell among 10,000 to 100,000 normal cells in clinical samples. The vast majority of cases have antigen-receptor gene rearrangements and leukemia immunophenotypes for MRD monitoring; about half of the cases currently have suitable gene fusions. The clinical significance of MRD has been conclusively demonstrated in both childhood and adult ALL. In most studies, MRD positivity is defined by the presence of 0.01% or more ALL cells; the risk of relapse is generally proportional to the level of MRD, particularly when measured during or at the end of remission-induction therapy. The prevalence of MRD during early therapy differs among genetic and biologic ALL subtypes. However, being a measurement of drug resistance in vivo and reflecting multiple cellular, host, and treatment variables, MRD is typically an independent prognostic factor. MRD is now used in several clinical trials for risk assignment and to guide clinical management overall. The time points at which MRD testing is performed and the threshold levels that trigger treatment intensification vary according to the methodology available, the results of preclinical correlative studies, and protocol design.<\/jats:p>","DOI":"10.1182\/asheducation-2010.1.7","type":"journal-article","created":{"date-parts":[[2011,1,16]],"date-time":"2011-01-16T19:08:48Z","timestamp":1295204928000},"page":"7-12","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":156,"title":["Minimal Residual Disease in Acute Lymphoblastic Leukemia"],"prefix":"10.1182","volume":"2010","author":[{"given":"Dario","family":"Campana","sequence":"first","affiliation":[{"name":"Departments of Oncology and Pathology, St. Jude Children's Research Hospital, and Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111717442074800_B1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0145-2126(81)90002-3","article-title":"Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia","volume":"5","author":"Bradstock","year":"1981","journal-title":"Leuk Res"},{"key":"2019111717442074800_B2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.hoc.2009.07.010","article-title":"Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia","volume":"23","author":"Campana","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111717442074800_B3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18\u201320 September 2008","volume":"24","author":"Bruggemann","year":"2010","journal-title":"Leukemia"},{"key":"2019111717442074800_B4","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"2019111717442074800_B5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/leu.2008.5","article-title":"Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia","volume":"22","author":"Flohr","year":"2008","journal-title":"Leukemia"},{"key":"2019111717442074800_B6","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/blood-2009-11-253435","article-title":"Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia","volume":"115","author":"Stow","year":"2010","journal-title":"Blood"},{"key":"2019111717442074800_B7","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Bruggemann","year":"2006","journal-title":"Blood"},{"key":"2019111717442074800_B8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"key":"2019111717442074800_B9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111717442074800_B10","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"2019111717442074800_B11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2006-01-0066","article-title":"A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome","volume":"108","author":"Coustan-Smith","year":"2006","journal-title":"Blood"},{"key":"2019111717442074800_B12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cyto.b.20516","article-title":"Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group","volume":"78","author":"Dworzak","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"2019111717442074800_B13","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors. A Children's Oncology Group Study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"2019111717442074800_B14","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"key":"2019111717442074800_B15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.leu.2403348","article-title":"Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"18","author":"Neale","year":"2004","journal-title":"Leukemia"},{"key":"2019111717442074800_B16","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3324\/haematol.2008.000414","article-title":"Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting","volume":"94","author":"Irving","year":"2009","journal-title":"Haematologica"},{"key":"2019111717442074800_B17","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"2019111717442074800_B18","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/leu.2009.17","article-title":"Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol","volume":"23","author":"van der Velden","year":"2009","journal-title":"Leukemia"},{"key":"2019111717442074800_B19","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1200\/JCO.2008.16.1117","article-title":"Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials","volume":"26","author":"Attarbaschi","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111717442074800_B20","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1200\/JCO.2008.20.8934","article-title":"Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow","volume":"27","author":"Basso","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111717442074800_B21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2002-01-0006","article-title":"Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"key":"2019111717442074800_B22","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-04-082040","article-title":"Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of \u201cisolated\u201d and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group","volume":"110","author":"Hagedorn","year":"2007","journal-title":"Blood"},{"key":"2019111717442074800_B23","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: A Children's Oncology Group Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111717442074800_B24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111717442074800_B25","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","article-title":"Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06\/99 and 07\/03 trials","volume":"109","author":"Raff","year":"2007","journal-title":"Blood"},{"key":"2019111717442074800_B26","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of MRD in adult ALL","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"2019111717442074800_B27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3324\/haematol.10965","article-title":"Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia","volume":"92","author":"Spinelli","year":"2007","journal-title":"Haematologica"},{"key":"2019111717442074800_B28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2009.07941.x","article-title":"Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII\/ECOG2993","volume":"148","author":"Patel","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111717442074800_B29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.2008.07185.x","article-title":"Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4\u20132002 MRD Study","volume":"142","author":"Holowiecki","year":"2008","journal-title":"Br J Haematol"},{"key":"2019111717442074800_B30","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/bmt.2009.308","article-title":"Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL","volume":"45","author":"Giebel","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2019111717442074800_B31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","article-title":"Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"106","author":"Wassmann","year":"2005","journal-title":"Blood"},{"key":"2019111717442074800_B32","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.leu.2403683","article-title":"Significant reduction of the hybrid BCR\/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia","volume":"19","author":"Pane","year":"2005","journal-title":"Leukemia"},{"key":"2019111717442074800_B33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.2008.07377.x","article-title":"Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy","volume":"143","author":"Yanada","year":"2008","journal-title":"Br J Haematol"},{"key":"2019111717442074800_B34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2006-01-024729","article-title":"Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)","volume":"109","author":"Schultz","year":"2007","journal-title":"Blood"},{"key":"2019111717442074800_B35","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2008.1.366","article-title":"Molecular determinants of treatment response in acute lymphoblastic leukemia","author":"Campana","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2019111717442074800_B36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"key":"2019111717442074800_B37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"key":"2019111717442074800_B38","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood-2007-01-068478","article-title":"A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia","volume":"110","author":"Flotho","year":"2007","journal-title":"Blood"},{"key":"2019111717442074800_B39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jama.2009.7","article-title":"Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia","volume":"301","author":"Yang","year":"2009","journal-title":"JAMA"},{"key":"2019111717442074800_B40","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2009-05-218560","article-title":"Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia","volume":"115","author":"Kang","year":"2010","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/7\/1492542\/bep00110000007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/7\/1492542\/bep00110000007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T05:30:05Z","timestamp":1712122205000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2010\/1\/7\/96417\/Minimal-Residual-Disease-in-Acute-Lymphoblastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,4]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2010.1.7","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,4]]}}}